50 results on '"Perryman, Alexander L."'
Search Results
2. Blind prediction of HIV integrase binding from the SAMPL4 challenge
3. The A–Z of Zika drug discovery
4. Machine Learning Platform to Discover Novel Growth Inhibitors of Neisseria gonorrhoeae
5. Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib
6. Discovery of New Zika Protease and Polymerase Inhibitors through the Open Science Collaboration Project OpenZika
7. Naïve Bayesian Models for Vero Cell Cytotoxicity
8. Predicting Mouse Liver Microsomal Stability with “Pruned” Machine Learning Models and Public Data
9. Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ
10. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306
11. Rickettsia Aglow: A Fluorescence Assay and Machine Learning Model to Identify Inhibitors of Intracellular Infection
12. Virtual screening of integrase inhibitors by large scale binding free energy calculations: the SAMPL4 challenge
13. Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein–ligand binding challenge
14. Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant Staphylococcus aureus
15. Correction to “Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery”
16. Pruned Machine Learning Models to Predict Aqueous Solubility
17. Fragment-Based Screen against HIV Protease
18. Optimization and Computational Evaluation of a Series of Potential Active Site Inhibitors of the V82F/I84V Drug-resistant Mutant of HIV-1 Protease: an Application of the Relaxed Complex Method of Structure-based Drug Design
19. Intrabacterial Metabolism Obscures the Successful Prediction of an InhA Inhibitor of Mycobacterium tuberculosis
20. Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA
21. Comparing and Validating Machine Learning Models forMycobacterium tuberculosisDrug Discovery
22. Novel Pyrimidines as Antitubercular Agents
23. Accessible Machine Learning Approaches for Toxicology
24. OpenZika : An IBM World Community Grid Project to Accelerate Zika Virus Drug Discovery
25. Molecular dynamics simulations of Zika virus NS3 helicase: Insights into RNA binding site activity
26. Addressing the Metabolic Stability of Antituberculars through Machine Learning
27. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells
28. Intrabacterial Metabolism Obscures the Successful Prediction of an InhA Inhibitor of Mycobacterium tuberculosis.
29. Non-classical transpeptidases yield insight into new antibacterials
30. OpenZika: An IBM World Community Grid Project to Accelerate Zika Virus Drug Discovery
31. Machine Learning Model Analysis and Data Visualization with Small Molecules Tested in a Mouse Model of Mycobacterium tuberculosis Infection (2014–2015)
32. Predicting Mouse Liver Microsomal Stability with “Pruned” Machine Learning Models and Public Data
33. A Virtual Screen Discovers Novel, Fragment-Sized Inhibitors ofMycobacterium tuberculosisInhA
34. Computational drug design accommodating receptor flexibility: The relaxed complex scheme
35. Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
36. Biological Evaluation of Potent Triclosan‐Derived Inhibitors of the Enoyl–Acyl Carrier Protein Reductase InhA in Drug‐Sensitive and Drug‐Resistant Strains of Mycobacterium tuberculosis
37. Comparing and Validating Machine Learning Models for Mycobacterium tuberculosisDrug Discovery
38. Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV Protease
39. Non-classical transpeptidases yield insight into new antibacterials
40. Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease
41. A Virtual Screen Discovers Novel, Fragment-Sized Inhibitors of Mycobacterium tuberculosis InhA.
42. Restrained molecular dynamics simulations of HIV‐1 protease: The first step in validating a new target for drug design
43. HIV‐1 protease molecular dynamics of a wild‐type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs
44. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme
45. AutoDocking Dinucleotides to the HIV-1 Integrase Core Domain: Exploring Possible Binding Sites for Viral and Genomic DNA
46. Computational Drug Design Accommodating Receptor Flexibility: The Relaxed Complex Scheme
47. Re-clustering the database for crystallization of macromolecules
48. Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.
49. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme.
50. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosisDemethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.